PureTech Health signed a research collaboration deal with Germany’s Boehringer Ingelheim to develop novel product candidates using the Boston-based and London-listed company’s proprietary lymphatic targeting technology for immune modulation.
What are key trends in the transparency compliance landscape? And, how are life sciences manufacturers tackling growing requirements
Catalent Inc. will buy privately held Paragon Bioservices Inc. for $1.2 billion in cash, bolstering the contract drugmaker’s capabilities to make gene therapy drugs for biotech clients.
Bristol-Myers Squibb’s shareholders voted to approve the drugmaker’s $74 billion takeover of Celgene despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.
Swiss drugmaker Novartis AG sued Amgen Inc., accusing the U.S. biotechnology company of trying to wrongfully back out of agreements to jointly develop and market the migraine prevention drug Aimovig and keep the profits for itself.
Durham, N.C.-based Precision BioSciences set the company’s initial public offering price at $16 per share, raising $126.4 million.
Bristol-Myers Squibb Co.’s top shareholder Wellington Management does not support the U.S. drugmaker’s $74 billion deal to buy biotech Celgene Corp., imperiling what would be the largest pharmaceutical acquisition of all time.
Sarepta Therapeutics will buy privately held gene therapy company Myonexus Therapeutics for $165 million, moving deeper into an emerging and lucrative field within the biotech sector.
Amgen Inc. said a U.S. jury confirmed the validity of patents on the biotech company’s cholesterol drug Repatha, rejecting a challenge by Regeneron Pharmaceuticals Inc. and Sanofi SA.
5AM Ventures raised a total of $497 million for two more funds.
AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma
AbbVie Inc., along with Teneobio Inc. and that company’s affiliate TeneoOne Inc., announced that they have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.